Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Inhibrx Biosciences, Inc
Inhibrx Biosciences, Inc
Rise Therapeutics LLC
Skin Analytics Limited
Revolution Medicines, Inc.
Pfizer
Center for Biomedical Research, Inc.
Revolution Medicines, Inc.
Seagen Inc.
Revolution Medicines, Inc.
MultiVir, Inc.